siRNA

MISSION® In Vivo Quality and iScale Oligos™ siRNA

MISSION In Vivo Quality siRNA are a superior quality siRNA suitable for RNAi research in animals, including target validation and pre-clinical siRNA testing. iScale Oligos siRNA synthesis allows for intermediate scales and a variety of available modifications. MISSION In Vivo Quality siRNA are appropriate for direct delivery or as an essential component of your formulation strategy.

Available for Custom siRNA and all MISSION Predesigned siRNA
MISSION In Vivo Quality and iScale Oligos siRNA gives you the quantity of siRNA and high purity requirements necessary for successful in vivo RNAi.

Ready to order your custom sequence at the 50 OD (3 mg) scale in standard Desalt or HPLC purification?
Click here, go to "Standard siRNA Ordering" and choose 50 OD from the pulldown menu.
Looking for larger scales? Please fill out the MISSION In Vivo Quality and iScale Oligos siRNA Inquiry and Order Request Form. Click here.

Demonstrated Use In Vivo
Sigma-Aldrich® teamed up with Bioo Scientific™ to validate our MISSION In Vivo Quality siRNA (see article in Drug Discovery & Development).

In these experiments, H1155luc cells were injected into NOD/SCID mice. Tumors formed and were injected with luciferase specific siRNA or non-targeting MISSION In Vivo Quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II. After 24 hours, D-luciferin solution was injected and the animals were imaged using the Night OWL instrument. Animals treated with luciferase specific siRNA showed significant reduction of luciferase activity while non-targeting siRNA treated animals were positive for luminescence (Figure 1). These data demonstrate the effectiveness of MISSION In Vivo Quality siRNA formulated in MaxSuppressor™ In Vivo RNA-LANCEr II in vivo delivery agent.

Luciferase specific siRNA treated animal image
Figure 1 – Luciferase specific siRNA treated animal on the left; non-targeting siRNA treated animal on the right. (click image to enlarge)

72 hours post-injection, the tumors were removed and the protein was extracted and normalized using a Bradford assay. Luciferase concentrations were assayed using a Luciferase ELISA. Protein reduction is represented relative to a non-targeting RNAi agent treated animal. Luciferase activity was reduced by two-fold in the tumors (Figure 2).

Luciferase Protein Chart image
Figure 2 – Each replicate is a different mouse (click image to enlarge)

 


MISSION In Vivo Quality siRNA Requirements:

  • HPLC (≥90% pure)
  • Removal of residual salts
  • Sterile filtered
  • Endotoxin tested

For more details about the MISSION In Vivo Quality and iScale Oligos siRNA requirements, click here.

 

Large-scale, Clean room quality manufacturing
Synthesis and purification of MISSION In Vivo Quality siRNA are performed under the highest manufacturing and quality standards.
  Large-scale, Clean room quality manufacturing image

Scales available:

  • 3 mg (50 OD): Perfect for Pilot Studies
  • 50 mg
  • 100 mg
  • Other sizes and purity options available – please inquire

 

For tracking of siRNA or improved stability in vivo, a wide variety of modifications are available for MISSION In Vivo Quality and iScale Oligos siRNA:

  • 5' FAM
  • 5' Phosphorylation
  • 5' Cyanine 5
  • 5' Cyanine 3
  • 5' Cyanine 5.5
  • 5' Amino
  • 5' Biotin
  • Phosphorothioate linkages
  • 2'-OMe
  • 3' Cholesterol
  • Other modifications – please inquire

 

Highest Quality Purity Standards for MISSION In Vivo Quality siRNA

RP-HPLC Chromatography graph image
Figure 3 (click image to enlarge)

 


Not sure how to get started?

Email us at MISSIONRNAI@sial.com.

For all other MISSION In Vivo Quality and iScale Oligos siRNA requests, please click on the form link below, and a Sigma Custom Products representative will contact you shortly.
MISSION In Vivo Quality and iScale Oligos siRNA Inquiry and Order Request Form

To contact Sigma Custom Products directly, please email:
acctreps-hou@sial.com

Custom iScale Oligos DNA oligonucleotides are also available.

 


Selected References for In Vivo Applications

  • Stany, M.P., et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 6(7):e21121. [Epub ahead of print] (2011).
  • Beghin, A., et al. ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. PLoS One. 4(10):e7478 (2009).
  • Ramachandran, V., et al. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 4(10):e7502. (2009).
  • Fitamant, J., et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A. 105(12):4850-5. [Epub ahead of print] (2008).
  • Brahmamdam, P., et al. Targeted delivery of siRNA to cell death proteins in sepsis. Shock Nov 11 [Epub ahead of print] (2008). (This reference uses Sigma's MISSION In Vivo Quality siRNA.)
  • Watabe, M., et al. A dominant role of GTRAP3-18 in neuronal glutathione synthesis. J. Neurosci. 28, 9404-13 (2008). (This reference uses Sigma’s MISSION In Vivo Quality siRNA.)
  • Kleinman, M. E. et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-7 (2008).
  • Yang, Z. et al. Toll-like Receptor 3 and Geographic Atrophy in Age-Related Macular Degeneration. N. Engl. J. Med. Aug 27 [Epub ahead of print] (2008).
  • Robbins, M. et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene Ther. Aug 19 [Epub ahead of print] (2008).

Click here for more In Vivo Applications References

 


MISSION Predesigned and Pre-arrayed MISSION siRNA Libraries Ordering Information

MISSION Predesigned siRNA

MISSION siRNA Human Druggable Genome

MISSION siRNA Rat Druggable Genome

MISSION siRNA Mouse Kinase Library

 


Contact Us

For questions about the library, pricing and quotes or other concerns, please email us at: MISSIONRNAI@sial.com.

MISSION is a registered trademark of Sigma-Aldrich Co. LLC Label License.

back to top